Wang Ji-Shi
Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, Guizhou Province, China,E-mail：
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Jun;28(3):1069-1074. doi: 10.19746/j.cnki.issn.1009-2137.2020.03.059.
Abstract Acute myeloid leukemia (AML) is a malignant clonal proliferative hematological tumor that originates from hematopoietic stem progenitor cells. Traditional chemotherapy can achieve complete remission in most patients, but so far, only allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure AML. Recurrence, drug resistance, and transplant-related deaths remain a key issue for AML treatment. Therefore, finding new treatments to improve the prognosis of patients with AML is urgently needed. In recent years, the emergence of new immunotherapy has revolutionized the concept of cancer treatment in the past few decades. Cellular immunotherapy represented by chimeric-antigen receptor T cell (CAR-T) and immunological detection point inhibitor represented by PD-1 blockade have achieved remarkable effects in hematological malignancies. This article mainly reviews the recent research progress of CAR-T and PD-1 blockade in the clinical treatment of AML.
摘要 急性髓系白血病（AML）是一种起源于造血干祖细胞的恶性克隆性增殖性血液肿瘤。传统化疗可使大多数患者达到完全缓解，但迄今为止，只有异基因造血干细胞移植（allo-HSCT）是治愈AML的唯一方法。复发、耐药和移植相关死亡仍然是AML治疗的关键问题。因此，迫切需要寻找新的治疗方法来改善AML患者的预后。近年来，新型免疫疗法的出现彻底改变了过去几十年来癌症治疗的理念。以嵌合抗原受体T细胞（CAR-T）为代表的细胞免疫疗法和以PD-1阻断为代表的免疫检查点抑制剂在血液系统恶性肿瘤中取得了显著疗效。本文主要综述CAR-T和PD-1阻断在AML临床治疗中的最新研究进展。
